Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: roivant.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2025 | $16.00 | Buy | Citigroup |
| 7/10/2025 | $19.00 | Buy | Goldman |
| 2/15/2024 | $17.00 | Outperform | Wolfe Research |
| 1/5/2024 | $20.00 | Overweight | Piper Sandler |
| 12/12/2023 | $14.00 | Buy | Deutsche Bank |
| 10/17/2023 | $17.00 | Buy | Guggenheim |
| 6/8/2023 | $10.50 | Neutral | BofA Securities |
| 10/27/2022 | $7.00 | Overweight | JP Morgan |
| 5/23/2022 | $6.00 | Outperform | SVB Leerink |
| 4/29/2022 | $15.00 | Overweight | Cantor Fitzgerald |
Fastest customizable press release news feed in the world
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001)All brepocitinib 45 mg patients achieved a clinically meaningful response, with 100% demonstrating at least a 10-point improvement on CSAMI-AOn the Investigator's Global Assessment (IGA), 69% percent of brepocitinib 45 mg patients compared to 0% of placebo patients achieved the gold standard two-point improvement to "Clear" (0) or "Almost Clear" (1) (Δ 69% P=.0047)Brepocitinib 15 mg patients also improved considerably, with numerically similar improvement to the 45 mg arm on lower-bar endpoin
PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung diseaseTopline results on track for second half of calendar year 2026 WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (NASDAQ:ROIV) company, today announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening conditi
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About ImmunovantImmunovant,
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call.
Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution, Roivant announces positive updates to timing guidance across four key programs: Brepocitinib NDA filing in dermatomyositis (DM) now expected in early calendar year 2026; commercial preparation underway with launch expected early in calendar year 2027Brepocitinib Phase 3 trial in non-infectious uveitis (NIU) fully enrolled with topline data now expected in the second half of calendar year 2026Brepocitinib proof-of-concept trial in cutaneous sarcoidosis (CS) fully enrolled with topline data now e
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints in Phase 3 VALOR study in dermatomyositis (DM), with NDA filing planned for the first half of calendar year 2026Brepocitinib program continues to advance with rapid enrollment in Phase 3 study in non-infectious uveitis (NIU) and proof-of-concept trial in cutaneous sarcoidosis (CS), with readouts expec
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended September 30, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call.
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About Immunovant Immunovant, Inc. is a cl
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onsetOn the primary endpoint, brepocitinib 30 mg achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo (p=0.0006), even with nearly twice as many patients coming off background steroids on brepocitinib 30 mg compared to placeboMore than two thirds of brepocitinib 30 mg patients experienced at least a moderate response (TIS≥40), and nearly half experienced a major respon
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
10-Q - Roivant Sciences Ltd. (0001635088) (Filer)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
10-Q - Roivant Sciences Ltd. (0001635088) (Filer)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
144 - Roivant Sciences Ltd. (0001635088) (Subject)
S-3ASR - Roivant Sciences Ltd. (0001635088) (Filer)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00
Goldman resumed coverage of Roivant Sciences with a rating of Buy and set a new price target of $19.00
Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00
Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00
Deutsche Bank initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00
Guggenheim initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $17.00
BofA Securities initiated coverage of Roivant Sciences with a rating of Neutral and set a new price target of $10.50
JP Morgan initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $7.00
SVB Leerink initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $15.00
Live Leadership Updates
NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T
Dr. Srini Ramanathan has over 20 years of experience in drug development and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company's preclinical and clinical portfolioIn addition to internal pipeline programs, Roivant companies Proteovant Therapeutics and VantAI have formed external drug development partnerships with leading companies to further innovate in protein degradationCollaborations with Blueprint Medicines, Janssen, and Boehringer Ingelheim include aggregate contingent milestone payments of over $1 billion as well as product royalties BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 02, 2022 (GLOBE NEWSWIRE)
This live feed shows all institutional transactions in real time.
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
Live finance-specific insights
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About ImmunovantImmunovant,
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call.
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints in Phase 3 VALOR study in dermatomyositis (DM), with NDA filing planned for the first half of calendar year 2026Brepocitinib program continues to advance with rapid enrollment in Phase 3 study in non-infectious uveitis (NIU) and proof-of-concept trial in cutaneous sarcoidosis (CS), with readouts expec
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended September 30, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call.
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About Immunovant Immunovant, Inc. is a cl
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onsetOn the primary endpoint, brepocitinib 30 mg achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo (p=0.0006), even with nearly twice as many patients coming off background steroids on brepocitinib 30 mg compared to placeboMore than two thirds of brepocitinib 30 mg patients experienced at least a moderate response (TIS≥40), and nearly half experienced a major respon
First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up periodOf the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatmentTwo potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. E
BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phase 3 study in dermatomyositis (DM) remains on track for topline data readout in the second half of calendar year 2025, with last patient last visit completed in July; Roivant and Priovant hosted an investor event on brepocitinib in June to share details about the ongoing VALOR study, including pooled/blinded baseline data, clinical endpoints details and successful steroid tapering dataBrepocitinib program continues to advance with rapid enrollment in non-infe
BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call. About